Biogen Idec squares up to Carl Icahn
This article was originally published in Scrip
Executive Summary
Biogen Idec looks likely to engage Carl Icahn in a second proxy battle in less than 18 months as the firm urged its shareholders to resist the advances of the activist investor. Mr Icahn owns around 6% of the company and is its fourth-largest shareholder.